TP53 and melanoma: We have applied INDRA to three successively more ambitious use cases: (i) translating a diagram and accompanying text describing p53 regulation by DNA damage, (ii) modeling adaptive drug resistance in BRAFV600E melanoma cells exposed to the BRAF inhibitor vemurafenib, and (iii) constructing a large‐scale model of RAS‐mediated immediate‐early signaling based on a crowd‐sourced schematic drawing.